



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/884,183	06/19/2001	Bret S. Weinstein	45421/RAS/W397	2814
23676	7590	07/14/2006		
SHELDON & MAK, INC 225 SOUTH LAKE AVENUE 9TH FLOOR PASADENA, CA 91101				
			EXAMINER WOITACH, JOSEPH T	
			ART UNIT 1632	PAPER NUMBER

DATE MAILED: 07/14/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

**Application No.**

09/884,183

**Applicant(s)**

WEINSTEIN, BRET S.

**Examiner**

Joseph T. Voitach

**Art Unit**

1632

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 17 February 2006.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 5 and 6 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 5, 6 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

### **DETAILED ACTION**

This application filed June 19, 2001, claims benefit to provisional application 60/212,812, filed June 19, 2000.

Applicant's amendment filed February 17, 2006 has been received and entered. Claim 5 has been amended. Claims 1-4 and 7-20 have been canceled. Claims 5-6 are pending and currently under examination.

#### ***Claim Rejections - 35 USC § 112***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 7 rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention is withdrawn.

Cancellation of claim 7 has rendered the rejection moot.

#### ***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 5-6 stand rejected under 35 U.S.C. 102(b) as being anticipated by Lee *et al.* (Nature 329:669-674, April 1998).

Claim 5 has been amended to indicate that the step of allowing the animals to breed is preceded by determining their telomere length. The amendment to claim 5 is noted by Applicant, and it is argued that Lee *et al.* fail to provide a determination step prior to breeding as required by the amended claims. See Applicants amendment filed February 17, 2006, page 5. Applicant's arguments have been fully considered, but not found persuasive.

Examiner recognizes that for the breeding of G2-G6, Lee *et al.* do not teach that each successive generation is tested before mating, however wild type and G1 is tested and known (see page 671, first column). In this case, the teaching of Lee *et al.* who provides the analysis of Go/WT and G1 and the subsequent breeding and analysis for research purposes anticipate the instant claims. Lee *et al.* teach a mouse where the telomere length has been determined, and provide analysis of the mice for experimental purposes. Lee *et al.* provide a first population of mice and consecutive breeding of said progeny to provide six generations of offspring, and analyze the telomere length of each corresponding generation (see figure 1(1) for example). Further, Lee *et al.* analyze the correlation ion each generation of telomere length and affects on the reproductivie system, in particular the germ cells of both the female and male germ cells (see figures 1(d) and 2 for example).

Again, it is noted that neither claims 5 nor 6 have any active step wherein the telomere length is specifically modified, and given the guidance of the present specification requires simply the mating of two animals, and relying on the inherent property of the animal to result in any given type of progeny.

Claims 5-6 rejected under 35 U.S.C. 102(b) as being anticipated by Shiels *et al.* (Nature 399:316-317, May 27, 1999) is withdrawn.

Examiner agrees that the teaching of Shiels *et al.* fails to teach the claimed method as specifically amended. See also Applicants amendment filed February 17, 2006, page 6.

Applicant's arguments have been fully considered, and found persuasive.

### ***Conclusion***

No claim is allowed.

As noted previously, at the time of filing and today there exists multiple lines of inbred animals (mice, dogs, cats, cattle,...) and while the skilled artisan would acknowledge that there are phenotypic differences among various lines, none of the phenotypes are correlated with telomere length (for example the predisposition of one line of mice to diabetes or susceptibility to carcinogens). To the contrary rather than telomere length, other genotypic factors are important in determining the phenotype of a given animal (see for example review of Festing (Neurobiology 20:23-244, 1999)). Moreover, it is further noted that this is consistent with Applicant's own views that it is not telomere length by itself that may affect a phenotype, rather the mechanisms that control it (see Weinstein et al., Exp Gerontol. (2002 May) 37(5):615-27), and that the breeding of favorable phenotypes in laboratory animals may result in this loss of control not a consequence of telomere length itself.

**THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).


A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph Woitach whose telephone number is (571) 272-0739.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, can be reached at (571) 272-0735.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group analyst Dianiece Jacobs whose telephone number is (571) 272-0532.

Joseph T. Woitach



AV 16 32


(for example, phlebotomy, chronic infection, skin wounding, petactomy) might be able to elicit an age-dependent phenotype in old  $mTR^{+/-}$  mice. Preliminary analysis indicates that some  $G_1$   $mTR^{+/-}$  animals in two independent colonies exhibit erosive dermatitis, which might indicate a defect in dermal stem cells (H.W.L. and R.A.D., and E. H. Herrera, J. M. C. Caballero and M.A.B., unpublished observations). At present the limited sample size does not allow us to assign this phenotype unambiguously to the  $mTR$  deficiency, although studies are continuing.

On the basis of previous studies in lower organisms that show a temporal lag between telomere loss and diminished cell viability, we suspected that substantial telomere loss would be required before a compromised clinical condition became apparent. Thus, as described<sup>10</sup>, we have produced additional generations ( $G_2$ ,  $G_3$ ,  $G_4$ ,  $G_5$  and  $G_6$ ) of  $mTR^{+/-}$  mice from successive matings of homozygous-


null intercrosses. Avoidance of inbreeding in the later generations was achieved through regular cousin-mating schemes<sup>23</sup> of offspring produced from 20 different  $G_1$   $mTR^{+/-}$  matings; these  $G_1$  mating pairs were in turn derived from 10 different  $mTR^{+/-}$  intercrosses.

#### Reproductive system

Reproductive function is highly dependent on proper germ-cell expansion and development. All matings proved to be productive up to the fifth generation. However, a statistically significant decline in litter size became apparent in the  $G_4$  intercrosses (Fig. 1a,  $G_4$ ,  $P = 0.021$  compared with  $G_1$ ). No offspring were produced from eight different  $G_6$  intercrosses. Both sexes appear to be affected, as only one in eight  $G_6$  males and one in eight  $G_6$  females produced a litter when mated to a wild-type partner. Male reproductive system. As the number of spermatocyte



**Figure 1** Effects of lack of telomerase on the mouse reproductive system. **a**, Impaired reproductive function in late-generation  $mTR$ -deficient mice. Males aged 8–12 weeks and females aged 4–12 weeks of the same generation of telomerase-deficient mice were mated over a period of 2 months or longer;  $n$  indicates the number of mating pairs examined. The  $P$  values of each generation were calculated compared with  $G_1$  ( $G_2$ ,  $P = 0.063$ ;  $G_3$ ,  $P = 0.070$ ;  $G_4$ ,  $P = 0.021$ ; and  $G_5$ ,  $P = 0.004$ ). **b**, Testicular atrophy and testes weights. Scale bar, 5 mm. **c**, Uterine horns. Grossly dissected uterine horns (u) and ovaries (arrows) (scale bar, 5 mm) and haematoxylin and eosin (H&E) staining (magnification  $\times 50$ ). **d**, Ovarian structure and function. Oestrus-matched ovaries are shown at  $\times 50$  magnification (left). **e**, endometrium; M, myometrium; GF, Graafian follicle; CL, corpus lutea. The graphs show a weight comparison of ovaries, average egg yields following natural mating with a wild-type stud male, and the percentage of *in vitro* development of pre-implantation embryos. BC, blastocyst.



**Figure 2** Proliferation and apoptosis in the male germ-cell compartment. **a**, Histology of WT and  $G_6$  testes. Top: sections at low magnification ( $\times 50$ ) through WT testes and representative  $G_6$  testes show the diminished cellularity in the  $G_6$  testes although there are some tubules undergoing nearly normal spermatogenesis (left edge of  $G_6$  section). At higher magnification ( $\times 200$  bottom), all stages of spermatogenesis are well represented in WT seminiferous tubules, whereas most  $G_6$  tubules lack spermatogenesis yet retain Sertoli cells. In the  $G_6$  testes, the apparent local accumulation of Leydig cells in the interstitium is secondary to contraction of the seminiferous tubules and an overall decrease in testis volume. Sn, Sertoli cell; L, Leydig cell; Sp, spermatogonia; Sc, primary spermatocyte; ES, early spermatid; LS, late spermatid. **b**, Comparative BrdU incorporation and TUNEL assays. Relative to WT samples, there was an approximate reduction in BrdU-positive nuclei (arrows) of three- to fivefold for  $G_6$  mice and greater than 20- to 100-fold for  $G_3$  mice. In the TUNEL (TdT) assay,  $G_6$  seminiferous tubules and  $G_3$  tubules with adequate cellularity for comparative analysis possessed many TUNEL-stained germ-cell nuclei (arrows), whereas only an occasional apoptotic cell was detected in the WT samples. Magnification  $\times 100$ .